Individualized aflibercept treatment protocol for BRVO achieves good long-term outcomes

Posted on

An individualized treatment protocol in treatment-naïve eyes with branch retinal vein occlusion (BRVO) with macular edema produced satisfactory long-term visual outcomes, according to a study.

In this study, patients were treated with an initial aflibercept injection and examined every 2 weeks until edema occurred, at which point they received a second injection. The time between the 2 injections was considered the period of efficacy and personalized treatment intervals were defined as 1 week shorter than the period of efficacy.

After reexamination, patients received aflibercept injections at their personalized treatment intervals.

After the initial injection, 37 eyes (n = 48 patients) experienced recurrence with a mean period of efficacy of 92.5 ± 40.8 days. Prior to recurrence, patients had a mean of 7.6 ± 2.9 visits.

At the end of the study period (24 months), the mean best corrected visual acuity (BCVA) was significantly better than at baseline, however, it was significantly worse than the best BCVA during the period of efficacy. Central macular thickness (CMT) was also significantly lower than at baseline but no different from the mean best CMT.

At 24 months, the mean gain of BCVA was 0.07 ± 0.18 logMAR, and there was a mean total number of visits of 15.8 ± 3.4.

Noma H, Yasuda K, Narimatsu A, et al. New individualized aflibercept treatment protocol for branch retinal vein occlusion with macular edema. Sci Rep. 2023;13(1):1536. doi: 10.1038/s41598-023-28533-z. PMID: 36707696.